Table 2.
Baseline demographic and clinical characteristics
| RFB (n = 125) | CB (n = 250) | P-value | |
|---|---|---|---|
| Age (years) | 64.91 ± 12.01 | 63.23 ± 11.02 | 0.84 |
| Gender (male) | 69 (55.20%) | 148 (59.20%) | 0.62 |
| BMI (kg/m2) | 28.92 ± 5.23 | 30.12 ± 4.94 | 0.33 |
| CHA2DS2-VASc score | 1.91 ± 1.23 | 2.02 ± 1.41 | 0.59 |
| Hypercholesterolaemia (n, %) | 69 (55.20%) | 123 (49.20%) | 0.37 |
| Diabetes (n, %) | 27 (21.60%) | 45 (18.00%) | 0.29 |
| Hypertension (n, %) | 59 (47.20%) | 114 (45.60%) | 0.55 |
| Heart failure (n, %) | 7 (5,60%) | 22 (8.8%) | 0.28 |
| Stroke or TIA (n, %) | 6 (4.80%) | 10 (4.00%) | 0.32 |
| CAD (n, %) | 15 (12.00%) | 37 (14.80%) | 0.11 |
| LVEF (%) | 55.05 ± 5.73 | 54.74 ± 6.81 | 0.71 |
| LAESVI (mL/m2) | 37.12 ± 10.84 | 39.03 ± 11.02 | 0.45 |
| EHRA symptom score | 3.11 ± 0.62 | 2.94 ± 0.32 | 0.77 |
| Prior cardioversion (n, %) | 27 (21.60%) | 60 (24.00%) | 0.29 |
| Time from AF diagnosis (months) | 11.51 ± 7.82 | 12.41 ± 8.64 | 0.26 |
| Drugs | |||
| AADs Class Ic (n, %) | 25 (20.00%) | 50 (20.00%) | 0.81 |
| AADs Class III (n, %) | 52 (41.60%) | 100 (40.00%) | 0.75 |
| OAC (n, %) | 111 (88.89%) | 223 (89.20%) | 0.74 |
| Follow-up | 12.41 ± 4.53 | 12.12 ± 5.32 | 0.31 |
AADs, anti-arrhythmic drugs; AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CB, cryoballoon; EHRA, European Heart Rhythm Association; LAESVI, left atrial end-systolic volume index; LVEF, left ventricular ejection fraction; OAC, oral anticoagulation; RFB, radiofrequency balloon; TIA, transient ischaemic attack.